Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To assess the progression-free survival of oral veliparib in combination with temozolomide or in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in subjects with BRCA1 or BRCA2 mutation and locally recurrent or metastatic breast cancer.
Critère d'inclusion
- BRCA1 or BRCA2 mutation metastatic breast cancer